Date de publication: 25 juin 2020
Promoteur – Intermédiaire Financier
EVAXION BIOTECH A/SLieu
Description
The project will finance the development of a platform for drug discovery exploiting Artificial Intelligence (AI) and the pipeline of potential vaccines and treatments targeting infectious diseases.
Objectifs
The aim is to support the R&D investments that are required in order to further advance the promoter's product pipeline and bring the products to market.
Secteur(s)
- Services - Activités spécialisées, scientifiques et techniques
Montant BEI envisagé (montant approximatif)
EUR 20 million
Coût total (montant approximatif)
EUR 45 million
Aspects environnementaux
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Passation des marchés
The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector project. Further details will be assessed during the project due diligence.
Statut
Signé - 6/08/2020
Clause de non-responsabilité
Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).